Muhamed Baljevic, MD

The panel looks ahead to the next 3 to 5 years of multiple myeloma treatment, highlighting emerging strategies that could further reshape the treatment landscape.

Dr. Hans Lee and Dr. Prashant Kapoor discuss strategies to expand access to CAR T-cell therapies and bispecific antibodies for patients with multiple myeloma, particularly in community oncology settings.

Dr. Hans Lee and Dr. Muhamed Baljevic discuss the emerging role of bispecific antibodies in frontline treatment for newly diagnosed multiple myeloma, focusing on data from the MajesTEC-5 study and other ongoing investigations.

Dr. Hans Lee and Dr. Prashant Kapoor discuss the potential role of talquetamab-based therapy in the evolving treatment sequence for relapsed/refractory multiple myeloma.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss treatment strategies for patients with multiple myeloma who relapse following BCMA-directed CAR T-cell therapy or bispecific antibodies.

Dr. Hans Lee, Dr. Prashant Kapoor, and Dr. Muhamed Baljevic discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, including its use across transplant-eligible and transplant-ineligible populations.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss supportive care considerations for patients receiving T-cell redirecting therapies, with a focus on infection prevention and mitigation of cytokine release syndrome (CRS) during bispecific antibody step-up dosing.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss evolving treatment strategies for early relapse and relapsed/refractory multiple myeloma, focusing on recent evidence for T-cell redirecting therapies.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss individualized treatment selection and sequencing in multiple myeloma as increasingly effective therapies expand available options.

Dr. Hans Lee and Dr. Prashant Kapoor discuss the evolving role of treatment duration and de-escalation in multiple myeloma, particularly for patients who achieve deep and sustained responses.

In this segment, Dr. Hans Lee and Dr. Muhamed Baljevic discuss treatment goals and evolving frontline strategies for multiple myeloma, with an emphasis on balancing disease control with long-term quality of life.

In this segment, Dr. Hans Lee introduces the rapidly evolving treatment landscape in multiple myeloma and outlines how advances in immunotherapy, quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping management across newly diagnosed and relapsed disease.

Drs Park and Baljevic discussed the evolution of myeloma management, including the integration of quadruplet therapies and bispecific antibodies.

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Muhamed Baljevic, MD, discusses the efficacy and safety of selinexor in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Muhamed Baljevic, MD, discusses the consideration of patient comorbidities and preferences during treatment selection in newly diagnosed myeloma.

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Muhamed Baljevic, MD, discusses the FDA approval of isatuximab-irfc in combination with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma.